Ludwig Enterprises (Ludwig Enterprises) Common Stock : $0.16 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Common Stock?

Ludwig Enterprises's quarterly common stock declined from Sep. 2023 ($0.32 Mil) to Dec. 2023 ($0.16 Mil) but then stayed the same from Dec. 2023 ($0.16 Mil) to Mar. 2024 ($0.16 Mil).

Ludwig Enterprises's annual common stock increased from . 20 ($0.00 Mil) to Dec. 2022 ($0.32 Mil) but then declined from Dec. 2022 ($0.32 Mil) to Dec. 2023 ($0.16 Mil).

Ludwig Enterprises Common Stock Historical Data

The historical data trend for Ludwig Enterprises's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises Common Stock Chart

Ludwig Enterprises Annual Data

Trend

Dec22

Dec23

Common Stock

0.32

0.16

Ludwig Enterprises Quarterly Data
	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial			0.32	-	0.32	0.16	0.16

Ludwig Enterprises Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Ludwig Enterprises (Ludwig Enterprises) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431

Website

https://www.ludwigent.com

Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.